Pub Date : 2021-09-15DOI: 10.31031/aics.2021.03.000558
K. Ikemoto
The case report showed multi-particulate high intensity of T2-weighted image of brain MRI in 30’s male heavy smoker suicidal attempt case, taken on psychiatric examination, 5 months later of his mild COVID-19 pneumonia. The MRI finding, indicating multiple micro-thrombosis is thought to be a cause of his depressed state and anosognosia.
{"title":"Multi-Particulate High Intensity of Brain MRI in 30’s Male Heavy Smoker Suicidal Attempt Case following Mild COVID-19 Pneumonia","authors":"K. Ikemoto","doi":"10.31031/aics.2021.03.000558","DOIUrl":"https://doi.org/10.31031/aics.2021.03.000558","url":null,"abstract":"The case report showed multi-particulate high intensity of T2-weighted image of brain MRI in 30’s male heavy smoker suicidal attempt case, taken on psychiatric examination, 5 months later of his mild COVID-19 pneumonia. The MRI finding, indicating multiple micro-thrombosis is thought to be a cause of his depressed state and anosognosia.","PeriodicalId":148950,"journal":{"name":"Advancements in Case Studies","volume":"311 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131646303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-26DOI: 10.31031/aics.2021.03.000556
R. Lauterbach
The first four weeks after birth seem to be a relatively safe period in relation to the first pandemic of the century. Although SARS-CoV-2 can be transmitted from the mother to the newborn through droplets, the clinical symptoms are usually nonsignificant and uncomplicated. It is especially truth when SARS-CoV-2 infection concerns the full-term newborn. We present the fatal disease course of COVID-19 in full term newborn delivered vaginally with appropriate weight and with Apgar score 10. On the fourteenth day of life, neonate rapidly deteriorated and within the next three days died of hyperglycemia that stimulated an inflammatory reaction.
{"title":"Case Report: Hyperglycemia-an Ominous Symptom of Disease Course of Covid-19 in Full-term Newborn","authors":"R. Lauterbach","doi":"10.31031/aics.2021.03.000556","DOIUrl":"https://doi.org/10.31031/aics.2021.03.000556","url":null,"abstract":"The first four weeks after birth seem to be a relatively safe period in relation to the first pandemic of the century. Although SARS-CoV-2 can be transmitted from the mother to the newborn through droplets, the clinical symptoms are usually nonsignificant and uncomplicated. It is especially truth when SARS-CoV-2 infection concerns the full-term newborn. We present the fatal disease course of COVID-19 in full term newborn delivered vaginally with appropriate weight and with Apgar score 10. On the fourteenth day of life, neonate rapidly deteriorated and within the next three days died of hyperglycemia that stimulated an inflammatory reaction.","PeriodicalId":148950,"journal":{"name":"Advancements in Case Studies","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126264678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-04DOI: 10.31031/aics.2021.03.000555
C. Baruah
Mucormycosis and aspergillosis have been recorded in alarmingly high numbers in India in recent decades. Even though fungal infections contribute significantly to human morbidity and mortality, the effect of these diseases on COVID-19 patients is unknown. Mucormycosis and aspergillosis were identified as two post-acute symptoms in COVID-19 patients in this study. Coronavirus 2 of the severe acute respiratory syndrome causes direct damage to the airway epithelium, allowing Mucormycosis and aspergillosis to invade. There were 8,848 infected and 219 dead cases of COVID-19-associated mucormycosis in India as of May 22, 2021. In addition, four Aspergillosis patients have been registered in Bihar, India. In India, a COVID-19-related yellow fungus case was also recorded for the first time. Both mild and moderate-to-severe illness tend to be affected by the syndrome. Despite the urgent need for efficient diagnostic tests, as well as safe and effective new drugs and vaccines, research into the pathophysiology of human fungal infections lags behind that of other
{"title":"Mucormycosis and Aspergillosis have been Linked to Covid-19-Related Fungal Infections in India","authors":"C. Baruah","doi":"10.31031/aics.2021.03.000555","DOIUrl":"https://doi.org/10.31031/aics.2021.03.000555","url":null,"abstract":"Mucormycosis and aspergillosis have been recorded in alarmingly high numbers in India in recent decades. Even though fungal infections contribute significantly to human morbidity and mortality, the effect of these diseases on COVID-19 patients is unknown. Mucormycosis and aspergillosis were identified as two post-acute symptoms in COVID-19 patients in this study. Coronavirus 2 of the severe acute respiratory syndrome causes direct damage to the airway epithelium, allowing Mucormycosis and aspergillosis to invade. There were 8,848 infected and 219 dead cases of COVID-19-associated mucormycosis in India as of May 22, 2021. In addition, four Aspergillosis patients have been registered in Bihar, India. In India, a COVID-19-related yellow fungus case was also recorded for the first time. Both mild and moderate-to-severe illness tend to be affected by the syndrome. Despite the urgent need for efficient diagnostic tests, as well as safe and effective new drugs and vaccines, research into the pathophysiology of human fungal infections lags behind that of other","PeriodicalId":148950,"journal":{"name":"Advancements in Case Studies","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123851721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-05-17DOI: 10.31031/aics.2021.03.000554
C. Yeoh
Severe cutaneous manifestations are commonly seen in drug hypersensitivity reactions which can present as pustular and bullous skin eruption. This can further progress and deteriorate into Steven-Johnsons syndrome or Toxic Epidermal Necrolysis syndrome (TENs) which require hospitalization. We report the case of a woman in her early fifties with metastatic melanoma who developed SJS and TENs 11 days following administration of Dabrafenib and Trametinib. Interestingly our patient had previously undergone 4 cycles of dual immunotherapy followed by single infusion of Nivolumab prior to this. Nivolumab had to be stopped due to grade 3 toxicity (hepatitis and hypoadrenalism). We believe this primed her immune system for potentially any hypersensitive reaction, in addition to attacking cancerous cells. Dabrafenib and Trametinib was commenced 18 days after discontinuation of immunotherapy. Our patient developed symptoms consistent with SJS and TEN, which was later confirmed on skin biopsy. She recovered well and following ITU admission and step down to oncology inpatient ward was discharged home. To our knowledge there are no links between Dabrafenib and SJS and TEN, although this has been reported in other BRAF inhibitors such as Vemurafenib. We changed her treatment to a third type of BRAF inhibitor, Encorafenib and Binimetinib (MEKtovi) which resulted in good Complete response control of her Melanoma for 6 months, to date. Epidermal Syndrome; (BRAF/MEKi): BRAF and inhibitor biologic
{"title":"Toxic Epidermal Necrolysis Following Dabrafenib and Trametinib for Stage 3c Locally Advanced Inoperable Melanoma: A Case Report","authors":"C. Yeoh","doi":"10.31031/aics.2021.03.000554","DOIUrl":"https://doi.org/10.31031/aics.2021.03.000554","url":null,"abstract":"Severe cutaneous manifestations are commonly seen in drug hypersensitivity reactions which can present as pustular and bullous skin eruption. This can further progress and deteriorate into Steven-Johnsons syndrome or Toxic Epidermal Necrolysis syndrome (TENs) which require hospitalization. We report the case of a woman in her early fifties with metastatic melanoma who developed SJS and TENs 11 days following administration of Dabrafenib and Trametinib. Interestingly our patient had previously undergone 4 cycles of dual immunotherapy followed by single infusion of Nivolumab prior to this. Nivolumab had to be stopped due to grade 3 toxicity (hepatitis and hypoadrenalism). We believe this primed her immune system for potentially any hypersensitive reaction, in addition to attacking cancerous cells. Dabrafenib and Trametinib was commenced 18 days after discontinuation of immunotherapy. Our patient developed symptoms consistent with SJS and TEN, which was later confirmed on skin biopsy. She recovered well and following ITU admission and step down to oncology inpatient ward was discharged home. To our knowledge there are no links between Dabrafenib and SJS and TEN, although this has been reported in other BRAF inhibitors such as Vemurafenib. We changed her treatment to a third type of BRAF inhibitor, Encorafenib and Binimetinib (MEKtovi) which resulted in good Complete response control of her Melanoma for 6 months, to date. Epidermal Syndrome; (BRAF/MEKi): BRAF and inhibitor biologic","PeriodicalId":148950,"journal":{"name":"Advancements in Case Studies","volume":"67 2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116656017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-04-01DOI: 10.31031/aics.2021.03.000553
L. Lemanski
We have discovered a cardiac-inducing RNA (CIR) in the axolotl, Ambystoma mexicanum , (a salamander) and two cardiac inducing RNAs (CIR-6 and CIR-30) in human heart that have the ability to induce the differentiation of non-muscle cells, including induced pluripotent stem cells from human skin, mouse embryonic stem cells, and mouse fibroblasts into cardiomyocytes in vitro . Although the primary sequences of salamander and human RNAs are not homologous, their secondary structures are very similar and we believe account for their shared unique abilities to promote differentiation of non-muscle cells into definitive cardiomyocytes. We are beginning to explore the potential for repair/regeneration of cardiac muscle in vivo using mouse and rat models with induced acute myocardial infarctions (AMI) to determine if pluripotent stem cells or fibroblasts transfected with the human CIRs or CIRs alone injected into the damaged areas of the hearts can affect repair of the damaged cardiac muscle tissue and return the infarcted hearts and the AMI animal models to pre-heart-attack function again. If cardiac cells damaged in heart attacks can be replaced with living, functioning cardiomyocytes, patients with heart disease would be able to have normal heart function restored and could return to normal pre-heart-attack activity levels. Understanding how CIR transforms non-muscle cells into vigorously contracting, functional cardiac muscle and effectively replacing damaged heart cells with newly-formed cardiac muscle tissue would represent a major breakthrough in modern biology and medicine with the potential to have a significant impact on the survival rate and quality of life of millions of individuals worldwide who suffer heart attacks each year.
{"title":"Cardiac Inducing RNAs (CIRs) from Human Fetal Heart Promote the Differentiation of Non-Muscle Cells to Form into Cardiomyocytes in vitro","authors":"L. Lemanski","doi":"10.31031/aics.2021.03.000553","DOIUrl":"https://doi.org/10.31031/aics.2021.03.000553","url":null,"abstract":"We have discovered a cardiac-inducing RNA (CIR) in the axolotl, Ambystoma mexicanum , (a salamander) and two cardiac inducing RNAs (CIR-6 and CIR-30) in human heart that have the ability to induce the differentiation of non-muscle cells, including induced pluripotent stem cells from human skin, mouse embryonic stem cells, and mouse fibroblasts into cardiomyocytes in vitro . Although the primary sequences of salamander and human RNAs are not homologous, their secondary structures are very similar and we believe account for their shared unique abilities to promote differentiation of non-muscle cells into definitive cardiomyocytes. We are beginning to explore the potential for repair/regeneration of cardiac muscle in vivo using mouse and rat models with induced acute myocardial infarctions (AMI) to determine if pluripotent stem cells or fibroblasts transfected with the human CIRs or CIRs alone injected into the damaged areas of the hearts can affect repair of the damaged cardiac muscle tissue and return the infarcted hearts and the AMI animal models to pre-heart-attack function again. If cardiac cells damaged in heart attacks can be replaced with living, functioning cardiomyocytes, patients with heart disease would be able to have normal heart function restored and could return to normal pre-heart-attack activity levels. Understanding how CIR transforms non-muscle cells into vigorously contracting, functional cardiac muscle and effectively replacing damaged heart cells with newly-formed cardiac muscle tissue would represent a major breakthrough in modern biology and medicine with the potential to have a significant impact on the survival rate and quality of life of millions of individuals worldwide who suffer heart attacks each year.","PeriodicalId":148950,"journal":{"name":"Advancements in Case Studies","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127166187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-10DOI: 10.31031/aics.2020.02.000550
Nazia Hossain
Background: Supra-venous serpentine dermatitis is a rare and self-limited cutaneous reaction to various chemotherapeutic agents. Case presentation: We describe a case of supra-venous serpentine dermatitis triggered by docetaxel in a middle-aged female patient who received chemotherapy for triple negative breast cancer. Lesions affected the chest, neck, and the arm that was used to infuse docetaxel. The diagnosis was based on skin biopsy results showing pathology consistent with an interface dermatitis. The patient was treated with oral and topical glucocorticoids. Her second cycle of chemotherapy was infused at a slower rate, preceded and followed by boluses of normal saline. Her acute reaction resolved after 2 weeks and she tolerated her second cycle of docetaxel-cyclophosphamide without issues. Conclusion: Oncologists and dermatologists should be aware of this potentially alarming reaction to docetaxel and other chemotherapeutic agents because adjustments to therapy are unnecessary and may result in undue harm as a result of suboptimal cancer treatment.
{"title":"Docetaxel-Induced Supravenous Serpentine Dermatitis: A Case Report","authors":"Nazia Hossain","doi":"10.31031/aics.2020.02.000550","DOIUrl":"https://doi.org/10.31031/aics.2020.02.000550","url":null,"abstract":"Background: Supra-venous serpentine dermatitis is a rare and self-limited cutaneous reaction to various chemotherapeutic agents. Case presentation: We describe a case of supra-venous serpentine dermatitis triggered by docetaxel in a middle-aged female patient who received chemotherapy for triple negative breast cancer. Lesions affected the chest, neck, and the arm that was used to infuse docetaxel. The diagnosis was based on skin biopsy results showing pathology consistent with an interface dermatitis. The patient was treated with oral and topical glucocorticoids. Her second cycle of chemotherapy was infused at a slower rate, preceded and followed by boluses of normal saline. Her acute reaction resolved after 2 weeks and she tolerated her second cycle of docetaxel-cyclophosphamide without issues. Conclusion: Oncologists and dermatologists should be aware of this potentially alarming reaction to docetaxel and other chemotherapeutic agents because adjustments to therapy are unnecessary and may result in undue harm as a result of suboptimal cancer treatment.","PeriodicalId":148950,"journal":{"name":"Advancements in Case Studies","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131196182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-03DOI: 10.31031/aics.2020.02.000549
A. Alshaali
Type 2 diabetes mellitus (T2DM) effect bone metabolism, but the relationship of T2DM with bone mineral density remains inconsistent across studies. The objective of this study was to determine the relationship between osteoporosis and T2DM in elderly patients.A total of 313 elderly was included in the study with a mean age of 68.20±7.07 years. The prevalence of osteoporosis in this study was 39.5%. The results showed that, nondiabetic elderly had higher prevalence of osteoporosis in comparison to diabetic elderly (44.0% and 33.1%, respectively). This difference was statistically significant (P=0.007). It was observed that males had higher femur and lumbar spine BMD in comparison with females. The present study gave better understanding of the effect of diabetes mellitus on bone architecture will help to improve the quality of provided health services at the primary health care level hence, improving the outcomes.
{"title":"The Relationship Between Type 2 Diabetes Mellitus and Osteoporosis in Elderly Patients: A Retrospective Study","authors":"A. Alshaali","doi":"10.31031/aics.2020.02.000549","DOIUrl":"https://doi.org/10.31031/aics.2020.02.000549","url":null,"abstract":"Type 2 diabetes mellitus (T2DM) effect bone metabolism, but the relationship of T2DM with bone mineral density remains inconsistent across studies. The objective of this study was to determine the relationship between osteoporosis and T2DM in elderly patients.A total of 313 elderly was included in the study with a mean age of 68.20±7.07 years. The prevalence of osteoporosis in this study was 39.5%. The results showed that, nondiabetic elderly had higher prevalence of osteoporosis in comparison to diabetic elderly (44.0% and 33.1%, respectively). This difference was statistically significant (P=0.007). It was observed that males had higher femur and lumbar spine BMD in comparison with females. The present study gave better understanding of the effect of diabetes mellitus on bone architecture will help to improve the quality of provided health services at the primary health care level hence, improving the outcomes.","PeriodicalId":148950,"journal":{"name":"Advancements in Case Studies","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130892504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-20DOI: 10.31031/aics.2020.02.000548
Lei Huang
Circulation has been considered in a sterile condition in individuals without live microbial infections. However, recent publications from our group and others highlight detection of blood microbiome or microbial molecules in healthy individuals and individuals with various diseases, as well as their potential roles in disease pathogenesis. In this review, we introduce the published studies and research advancement in the field of blood microbial and microbial translocation in disease immunopathogenesis.
{"title":"The Role of Blood Microbiome and Microbial Product Translocation in Disease Pathogenesis","authors":"Lei Huang","doi":"10.31031/aics.2020.02.000548","DOIUrl":"https://doi.org/10.31031/aics.2020.02.000548","url":null,"abstract":"Circulation has been considered in a sterile condition in individuals without live microbial infections. However, recent publications from our group and others highlight detection of blood microbiome or microbial molecules in healthy individuals and individuals with various diseases, as well as their potential roles in disease pathogenesis. In this review, we introduce the published studies and research advancement in the field of blood microbial and microbial translocation in disease immunopathogenesis.","PeriodicalId":148950,"journal":{"name":"Advancements in Case Studies","volume":"47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123599471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-28DOI: 10.31031/aics.2020.02.000546
Iraj Salehi Abari
The COVID-19 is a new contagious viral/immunological systemic disorder with predominantly respiratory features caused by human infection with SARS-CoV-2. From the time the virus enters the body to the time of initial symptoms of the disease, it is called the incubation period which ranges from one day to fourteen days. Initial presentation in the patients with mild COVID-19 is including mild fever, dry cough, fatigue and then body ache, anosmia, and lack of taste. About 40% of patients with COVID-19 are asymptomatic and, 40%; mild, 15%; severe, and 5% are critical COVID-19. A negative SARS-CoV-2 test does not rule out the diagnosis of COVID-19 and that a positive test does not necessarily indicate a COVID-19 diagnosis. The normal lungs in HRCT scan with a negative SARS-CoV-2 test does not preclude that the person has COVID-19. Patients may contract COVID-19 without any risk factors and have no symptoms. The authors conclude that to reject or confirm the diagnosis of COVID-19 by performing a SARS-CoV-2 kit test and the HRCT scanning of lungs may not be the gold standard for diagnosis of COVID-19. In other words, history is the key to COVID-19 diagnosis. Therefore, in this article, twenty cases of COVID-19 are presented, in most of which the diagnostic test of SARS-CoV-2 and HRCT scan of the lungs are negative.
{"title":"The Report of 20 Missed Real COVID-19 Cases","authors":"Iraj Salehi Abari","doi":"10.31031/aics.2020.02.000546","DOIUrl":"https://doi.org/10.31031/aics.2020.02.000546","url":null,"abstract":"The COVID-19 is a new contagious viral/immunological systemic disorder with predominantly respiratory features caused by human infection with SARS-CoV-2. From the time the virus enters the body to the time of initial symptoms of the disease, it is called the incubation period which ranges from one day to fourteen days. Initial presentation in the patients with mild COVID-19 is including mild fever, dry cough, fatigue and then body ache, anosmia, and lack of taste. About 40% of patients with COVID-19 are asymptomatic and, 40%; mild, 15%; severe, and 5% are critical COVID-19. A negative SARS-CoV-2 test does not rule out the diagnosis of COVID-19 and that a positive test does not necessarily indicate a COVID-19 diagnosis. The normal lungs in HRCT scan with a negative SARS-CoV-2 test does not preclude that the person has COVID-19. Patients may contract COVID-19 without any risk factors and have no symptoms. The authors conclude that to reject or confirm the diagnosis of COVID-19 by performing a SARS-CoV-2 kit test and the HRCT scanning of lungs may not be the gold standard for diagnosis of COVID-19. In other words, history is the key to COVID-19 diagnosis. Therefore, in this article, twenty cases of COVID-19 are presented, in most of which the diagnostic test of SARS-CoV-2 and HRCT scan of the lungs are negative.","PeriodicalId":148950,"journal":{"name":"Advancements in Case Studies","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130907747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-06-04DOI: 10.31031/aics.2020.02.000545
Zanluchi Vbs
{"title":"Case Report: Follow Up of a Patient with De Novo Mutation at Kcna2 Gene Leading to Ataxia and Epileptic Encephalopathy","authors":"Zanluchi Vbs","doi":"10.31031/aics.2020.02.000545","DOIUrl":"https://doi.org/10.31031/aics.2020.02.000545","url":null,"abstract":"","PeriodicalId":148950,"journal":{"name":"Advancements in Case Studies","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124895468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：